Get started
Author

Mary Jane Timson

Observed names: M.J. Timson, Mary J Timson, Mary J. Timson
OpenAlex ID: A5089864580
Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti‐tumor efficacy
2024 · Yasmin Yu, Madhumita Bogdan, et al. · Molecular Oncology · 14
Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models
2022 · Martin McMahon, Madhumita Bogdan, et al. · Cancer Research · 10
Further Studies on the Role of Water in R67 Dihydrofolate Reductase
2013 · Mary Jane Timson, Michael R. Duff, et al. · Biochemistry · 9
Abstract P084: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with EGFR inhibitors osimertinib and afatinib in NSCLC preclinical models
2021 · Madhumita Bogdan, Mary J. Timson, et al. · Molecular Cancer Therapeutics · 8
Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers
2019 · Bryan D Smith, Lakshminarayana Vogeti, et al. · Molecular Cancer Therapeutics · 7
Abstract 4045: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models
2023 · Stacie L. Bulfer, Bertrand Le Bourdonnec, et al. · Cancer Research · 4
Abstract 4872: DCC-3116, a first-in-class selective ULK1/2 inhibitor of autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models
2023 · Madhumita Bogdan, Mary J. Timson, et al. · Cancer Research · 3
Abstract 1377: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with encorafenib and cetuximab in BRAF V600E mutant colorectal cancer models
2023 · Madhumita Bogdan, Mary J. Timson, et al. · Cancer Research · 2
Abstract C074: VPS34 inhibition delays activation-induced STING degradation to prolong STING signaling and improve anti-tumor efficacy in preclinical models
2023 · Madhumita Bogdan, Jodi Simeon, et al. · Molecular Cancer Therapeutics · 1
Author response for "Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti‐tumor efficacy"
2024 · Yasmin Yu, Madhumita Bogdan, et al. · Publons reviews and discussion
Getting Heavy: An Exploration into the Effects of D2O and High Hydrostatic Pressure on R67 Dihydrofolate Reductase
2011 · Mary Jane Timson
Characterization of a P2Y2 nucleotide receptor antibody by Western blot analysis [abstract]
2006 · Mary Jane Timson, Jean M. Camden, et al. · MOspace Institutional Repository (University of Missouri)
Works count: 13
Citation count: 58
H-index: 5
I10-index: 2
Year
Topic
Type